Clinical trial readout dates for Lantheus Holdings Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is August 2027.
| Phase 1/2 LNTH2403 Phase 1 dose Relapsed / Refractory Osteosarcoma · NCT07357519 | August 2027 Recruiting |
| Phase 3 [18F]PI-2620 Alzheimer Disease · NCT05641688 | March 2028 Recruiting |
| Phase 2/3 [68Ga]-LNTH-2401 Prostate Cancer · NCT07831824 | September 2029 Recruiting |
Lantheus Holdings Inc. reported $684M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $22M for that quarter.
| 8-K Other Events — often topline trial data | 2026-11-10 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |
| 8-K Other Events — often topline trial data | 2026-10-22 |